Koselugo 10 Mg/25 Mg Capsules

KOSELUGO as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above.

Treatment with KOSELUGO should be initiated by a doctor experienced in the diagnosis and the treatment of patients with NF1 related tumours.

Posology

The recommended dose of KOSELUGO is 25 mg/m2 of body surface area (BSA), taken orally twice daily (approximately every 12 hours). Dosing is individualised based on BSA (mg/m2) and rounded to the nearest achievable 5 mg or 10 mg dose (up to a maximum single dose of 50 mg). Different strengths of KOSELUGO capsules can be combined to attain the desired dose (Table 1).

Table 1. Recommended dose based on body surface area

Body surface area (BSA) a Recommended dose

• 0,55 - 0,69 m2 20 mg in the morning and 10 mg in the evening
• 0,70 - 0,89 m2 20 mg twice daily
• 0,90 - 1,09 m2 25 mg twice daily
• 1,10 - 1,29 m2 30 mg twice daily
• 1,30 - 1,49 m2 35 mg twice daily
• 1,50 - 1,69 m2 40 mg twice daily
• 1,70 - 1,89 m2 45 mg twice daily
• u22651,90 m2 50 mg twice daily

a The recommended dose for patients with a BSA less than 0,55 m2 has not been established.

Treatment with KOSELUGO should continue as long as clinical benefit is observed, or until PN progression or the development of unacceptable toxicity. There is limited data in patients older than 18, therefore continued treatment into adulthood should be based on benefits and risks to the individual patient as assessed by the doctor. However, start of treatment with KOSELUGO in adults is not appropriate.

Missed dose

If a dose of KOSELUGO is missed, it should only be taken if it is more than 6 hours until the next scheduled dose.

Vomiting

If vomiting occurs after KOSELUGO is administered, an additional dose is not to be taken. The patient should continue with the next scheduled dose.

Dose adjustments

Interruption and/or dose reduction or permanent discontinuation of KOSELUGO may be required based on individual safety and tolerability (see sections 4.4 and 4.8). Recommended dose reductions are given in Table 2 and may require the daily dose to be divided into two administrations of different strength or for treatment to be given as a once daily dose.

Table 2. Recommended dose reductions for adverse reactions

Body surface area (BSA) Initial KOSELUGO dose a (mg/twice daily) First dose reduction (mg/dose) Second dose reduction (mg/dose) b Morning Evening Morning Evening

• 0,55 u2013 0,69 m2 20 mg in the morning and 10 mg in the evening 10 10 10 mg once daily
• 0,70 - 0,89 m2 20 20 10 10 10
• 0,90 - 1,09 m2 25 25 10 10 10
• 1,10 - 1,29 m2 30 25 20 20 10
• 1,30 - 1,49 m2 35 25 25 25 10
• 1,50 - 1,69 m2 40 30 30 25 20
• 1,70 - 1,89 m2 45 35 30 25 20
• u2265 1,90 m2 50 35 35 25 25

a Based on BSA as shown in Table 1.

b Permanently discontinue treatment in patients unable to tolerate KOSELUGO after two dose reductions.

Dose modifications for the management of adverse reactions associated with this medicine are presented in Table 3.

Table 3. Recommended dose modifications for adverse reactions

CTCAE Grade* Recommended dose modification

• Grade 1 or 2 (tolerable - can be managed with supportive care) Continue treatment and monitor as clinically indicated
• Grade 2 (intolerable - cannot be managed with supportive care) or Grade 3 Interrupt treatment until toxicity is grade 0 or 1 and reduce by one dose level when resuming therapy (see Table 2)
• Grade 4 Interrupt treatment until toxicity is grade 0 or 1, reduce by one dose level when resuming therapy (see Table 2). Consider discontinuation

* Common Terminology Criteria for Adverse Events (CTCAE)

Dose modification advice for left ventricular ejection fraction (LVEF) reduction

In cases of asymptomatic LVEF reduction of u226510 percentage points from baseline and below the institutional lower level of normal (LLN), KOSELUGO treatment should be interrupted until resolution. Once resolved, KOSELUGO should be reduced by one dose level when resuming therapy (see Table 2). In patients who develop symptomatic LVEF reduction or a grade 3 or 4 LVEF reduction, KOSELUGO should be discontinued and a prompt cardiology referral should be carried out (see section 4.4).

Dose modification advice for ocular toxicities

KOSELUGO treatment should be interrupted in patients diagnosed with retinal pigment epithelial detachment (RPED) or central serous retinopathy (CSR) with reduced visual acuity until resolution; reduce KOSELUGO by one dose level when resuming therapy (see Table 2). In patients diagnosed with RPED or CSR without reduced visual acuity, ophthalmic assessment should be conducted every 3 weeks until resolution. In patients who are diagnosed with retinal vein occlusion (RVO), treatment with KOSELUGO should be permanently discontinued (see section 4.4).

Dose adjustments for co-administration with CYP3A4 or CYP2C19 inhibitors

Concomitant use of strong or moderate CYP3A4 or CYP2C19 inhibitors is not recommended and alternative agents should be considered. If a strong or moderate CYP3A4 or CYP2C19 inhibitor must be co-administered, the recommended KOSELUGO dose reduction is as follows:

• If a patient is currently taking 25 mg/m2 twice daily, dose reduce to 20 mg/m2 twice daily.
• If a patient is currently taking 20 mg/m2 twice daily, dose reduce to 15 mg/m2 twice daily (see Table 4 and section 4.5).

Table 4. Recommended dose to achieve 20 mg/m2 or 15 mg/m2 twice daily dose level

Body surface area 20 mg/m2 twice daily (mg/dose) 15 mg/m2 twice daily (mg/dose)

Morning Evening Morning Evening

• 0,55 - 0,69 m2 10 10 10 mg once daily
• 0,70 - 0,89 m2 20 10 10 10
• 0,90 - 1,09 m2 20 20 20 10
• 1,10 - 1,29 m2 25 25 25 10
• 1,30 - 1,49 m2 30 25 25 20
• 1,50 - 1,69 m2 35 30 25 25
• 1,70 - 1,89 m2 35 35 30 25
• u2265 1,90 m2 40 40 30 30

Special Populations

Renal impairment

Based on clinical trials no dose adjustment is recommended in patients with mild, moderate, severe renal impairment or those with end stage renal disease (ESRD) (see section 5.2).

Hepatic impairment

Based on clinical trials, no dose adjustment is recommended in patients with mild hepatic impairment. The starting dose should be reduced in patients with moderate hepatic impairment to 20 mg/m2 BSA, twice daily (see Table 4). KOSELUGO is contraindicated for use in patients with severe hepatic impairment (see sections 4.3 and 5.2).

Ethnicity

Increased systemic exposure has been seen in adult Asian subjects, although there is considerable overlap with Western subjects when corrected for body weight. No specific adjustment to the starting dose is recommended for paediatric Asian patients, however these patients should be closely monitored for adverse events (see section 5.2).

Paediatric population

The safety and efficacy of KOSELUGO in children less than 3 years of age has not been established. No data are available.

Method of administration

KOSELUGO is for oral use. It can be taken with or without food (see section 5.2). The capsules should be swallowed whole with water. The capsules should not be chewed, dissolved, or opened, because this could impair medicine release and affect the absorption of KOSELUGO. KOSELUGO should not be administered to patients who are unable or unwilling to swallow the capsule whole. Patients should be assessed for their ability to swallow a capsule before starting treatment. Standard medicine swallowing techniques are expected to be sufficient to swallow KOSELUGO capsules. For patients who have difficulties swallowing the capsule, referral to an appropriate health care professional such as a speech and language therapist could be considered to identify suitable methods that can be tailored to the particular patient.

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Severe hepatic impairment (see sections 4.2 and 5.2).

Left ventricular ejection fraction (LVEF) reduction

Asymptomatic decreases in ejection fraction have been reported in 26 % of paediatric patients in the pivotal clinical trial. Median time to initial onset of these adverse reactions was 232 days. A small number of serious reports of LVEF reduction associated with KOSELUGO have been reported in paediatric patients who participated in an expanded access program (see section 4.8).

Paediatric patients with a history of impaired left ventricular function or a baseline LVEF below institutional LLN have not been studied. LVEF should be evaluated by echocardiogram before initiation of treatment to establish baseline values. Prior to starting KOSELUGO treatment, patients should have an ejection fraction above the institutional LLN.

LVEF should be evaluated at approximately 3-month intervals, or more frequently as clinically indicated, during treatment. Reduction in LVEF can be managed using treatment interruption, dose reduction or treatment discontinuation (see section 4.2).

Ocular toxicity

Patients should be advised to report any new visual disturbances. Adverse reactions of blurred vision have been reported in paediatric patients receiving KOSELUGO. Isolated cases of RPED, CSR and RVO in adult patients with multiple tumour types, receiving treatment with KOSELUGO monotherapy and in combination with other anti-cancer agents, and in a single paediatric patient with pilocytic astrocytoma on KOSELUGO monotherapy, have been observed (see section 4.8).

In line with clinical practice an ophthalmological evaluation prior to treatment initiation and at any time a patient reports new visual disturbances is recommended. In patients diagnosed with RPED or CSR without reduced visual acuity, ophthalmic assessment should be conducted every 3 weeks until resolution. If RPED or CSR is diagnosed and visual acuity is affected, KOSELUGO therapy should be interrupted and the dose reduced when treatment is resumed (see section 4.2). If RVO is diagnosed, treatment with KOSELUGO should be permanently discontinued (see section 4.2).

Liver laboratory abnormalities

Liver laboratory abnormalities, specifically AST and ALT elevations, can occur with KOSELUGO (see section 4.8). Liver laboratory values should be monitored before initiation of KOSELUGO and at least monthly during the first 6 months of treatment, and thereafter as clinically indicated. Liver laboratory abnormalities should be managed with dose interruption, reduction or treatment discontinuation (see Table 2 in section 4.2).

Skin and subcutaneous disorders

Skin rash (including maculopapular rash and acneiform rash), paronychia and hair changes have been reported very commonly in the pivotal clinical study (see section 4.8). Dry skin, hair colour changes, paronychia and rash maculo-papular were seen more frequently in younger children (age 3-11 years) and acneiform rash was seen more frequently in post-pubertal children (age 12-16 years).

Vitamin E supplementation

Patients should be advised not to take any supplemental vitamin E. KOSELUGO 10 mg capsules contain 32 mg vitamin E as the excipient, D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). KOSELUGO 25 mg capsules contain 36 mg vitamin E as TPGS. High doses of vitamin E may increase the risk of bleeding in patients taking concomitant anticoagulant or antiplatelet medicines (e.g., warfarin or acetylsalicylic acid). Anticoagulant assessments, including international normalised ratio or prothrombin time, should be conducted more frequently to detect when dose adjustments of the anticoagulant or antiplatelet medicines are warranted (see section 4.5).

Risk of choking

KOSELUGO is available as a capsule which must be swallowed whole. Some patients, in particular children < 6 years of age, may be at risk of choking on a capsule formulation due to developmental, anatomical or psychological reasons. Therefore, KOSELUGO should not be administered to patients who are unable or unwilling to swallow the capsule whole (see section 4.2).

Women of child bearing potential

KOSELUGO is not recommended in women of child bearing potential who are not using contraception (see section 4.6).

Interaction studies have only been performed in healthy adults (aged u226518 years).

Active substances that may increase KOSELUGO plasma concentrations

Co-administration with a strong CYP3A4 inhibitor (200 mg itraconazole twice daily for 4 days) increased KOSELUGO Cmax by 19 % (90 % CI 4, 35) and AUC by 49 % (90 % CI 40, 59) in healthy adult subjects.

Co-administration with a strong CYP2C19/moderate CYP3A4 inhibitor (200 mg fluconazole once daily for 4 days) increased KOSELUGO Cmax by 26 % (90 % CI 10, 43) and AUC by 53 % (90 % CI 44, 63) in healthy adult subjects, respectively.

Concomitant use of erythromycin (moderate CYP3A4 inhibitor) or fluoxetine (strong CYP2C19/CYP2D6 inhibitor) is predicted to increase KOSELUGO AUC by ~30-40 % and Cmax by ~20 %.

Co-administration with strong inhibitors of CYP3A4 (e.g., clarithromycin, grapefruit juice, oral ketoconazole) or CYP2C19 (e.g., ticlopidine) should be avoided. Co-administration with moderate inhibitors of CYP3A4 (e.g., erythromycin and fluconazole) and CYP2C19 (e.g., omeprazole) should be avoided.

If co-administration is unavoidable, patients should be carefully monitored for adverse events and the KOSELUGO dose should be reduced (see section 4.2 and Table 4).

Active substances that may decrease KOSELUGO plasma concentrations

Co-administration with a strong CYP3A4 inducer (600 mg rifampicin daily for 8 days) decreased KOSELUGO Cmax by -26 % (90 % CI -17, -34) and AUC by -51 % (90 % CI -47, -54).

Concomitant use of strong CYP3A4 inducers (e.g., phenytoin, rifampicin, carbamazepine, St.Johnu2019s Wort) or moderate CYP3A4 inducers with KOSELUGO should be avoided.

Active substances whose plasma concentrations may be altered by KOSELUGO

In vitro, KOSELUGO is an inhibitor of OAT3. The potential for a clinically relevant effect on the pharmacokinetics of concomitantly administered substrates of OAT3 (e.g., methotrexate and furosemide) cannot be excluded (see section 5.2).

TPGS is a P-gp inhibitor in vitro and it cannot be excluded that it may cause clinically relevant medicine interactions with substrates of P-gp (e.g., digoxin or fexofenadine).

The effect of KOSELUGO on the exposure of oral contraceptives has not been evaluated. Therefore, use of an additional barrier method should be recommended to women using hormonal contraceptives (see section 4.6).

Effect of gastric acid reducing agents on KOSELUGO

KOSELUGO capsules do not exhibit pH dependent dissolution. KOSELUGO can be used concomitantly with gastric pH modifying agents (i.e., H2-receptor antagonists and proton pump inhibitors) without restrictions, except for omeprazole which is a CYP2C19 inhibitor.

Vitamin E KOSELUGO capsules contain vitamin E as the excipient TPGS. Therefore, patients should avoid taking supplemental vitamin E and anticoagulant assessments should be performed more frequently in patients taking concomitant anticoagulant or antiplatelet medicines (see section 4.4).

Women of childbearing potential/Contraception in males and females

Women of childbearing potential should be advised to avoid becoming pregnant while receiving KOSELUGO. It is recommended that a pregnancy test should be performed on women of childbearing potential prior to initiating treatment.

Both male and female patients (of reproductive potential) should be advised to use effective contraception during and for at least 1 week after completion of treatment with KOSELUGO. It cannot be excluded that KOSELUGO may reduce the effectiveness of oral contraceptives, therefore women using hormonal contraceptives should be recommended to add a barrier method (see section 4.5).

Pregnancy

There are no data on the use of KOSELUGO in pregnant women. Studies in animals have shown reproductive toxicity including embryofoetal death, structural defects and reduced foetal weights (see section 5.3). KOSELUGO is not recommended during pregnancy and in women of childbearing potential not using contraception (see section 4.4). If a female patient or a female partner of a male patient receiving KOSELUGO becomes pregnant, she should be apprised of the potential risk to the foetus.

Breastfeeding

It is not known whether KOSELUGO, or its metabolites, are excreted in human milk. KOSELUGO and its active metabolite are excreted in the milk of lactating mice (see section 5.3). A risk to the breast-fed child cannot be excluded, therefore breast-feeding should be discontinued during treatment with KOSELUGO.

Fertility

There are no data on the effect of KOSELUGO on human fertility. KOSELUGO had no impact on fertility and mating performance in male and female mice, although a reduction in embryonic survival was observed in female mice (see section 5.3).

KOSELUGO may have a minor influence on the ability to drive and use machines. Fatigue, asthenia and visual disturbances have been reported during treatment with KOSELUGO and patients who experience these symptoms should observe caution when driving or using machines.

Summary of the safety profile

The safety profile of KOSELUGO monotherapy in paediatric patients with NF1 who have inoperable PN has been determined following evaluation of a combined safety population of 74 paediatric patients (20-30 mg/m2 twice daily). This paediatric u2018poolu2019 of patients comprised 50 patients in SPRINT Phase II Stratum 1, treated with KOSELUGO 25 mg/m2 twice daily (the pivotal dataset) and 24 patients in SPRINT Phase I treated with 20 to 30 mg/m2 KOSELUGO twice daily (the dose finding study). There were no clinically relevant differences in the safety profile between SPRINT Phase I and SPRINT Phase II Stratum 1. This safety profile was also substantiated by a pool of safety data from 7 AstraZeneca sponsored studies in adult patients with multiple tumour types (N=347) who received 75 to 100 mg twice daily).

In the paediatric pool, the median total duration of KOSELUGO treatment in paediatric patients with NF1 who have PN was 55 months (range: 48 months and 16 % for >72 months. Patients aged u22652 to 11 years (N=45) had a higher incidence of the following adverse drug reactions (ADRs) compared to patients aged 12 to 18 years (N=29): hypoalbuminaemia, dry skin, pyrexia, hair colour changes, rash maculo-papular and paronychia.

In the paediatric pool (N=74; comprising 50 patients from the pivotal SPRINT Phase II Stratum 1 dataset and 24 patients from the supportive SPRINT Phase I dataset), the most common adverse reactions of any grade (incidence u226545 %) were vomiting (86 %), diarrhoea (81%), blood creatine phosphokinase increased (77 %), nausea (77 %), dry skin (65 %), pyrexia (61 %), dermatitis acneiform (61%), asthenic events (59 %), paronychia (57 %), stomatitis (55 %), haemoglobin decreased (54 %), non-acneiform rashes (53 %), hypoalbuminaemia (51 %), and aspartate aminotransferase increased (51 %). Dose interruptions and reductions due to adverse events were reported in 82 % and 39 % of patients, respectively. The most commonly reported ADRs leading to dose modification (dose interrupted or dose reduced) of KOSELUGO were vomiting (32 %), paronychia (23 %), nausea (19 %), diarrhoea (15 %) and pyrexia (11 %). Permanent discontinuation due to adverse events was reported in 12 % of the patients. The following serious adverse reactions were reported: diarrhoea (3 %), anaemia (3 %), pyrexia (3 %), blood CPK increased (3 %), blood creatinine increased (1 %), oedema peripheral (1 %) and vomiting (1 %).

Tabulated list of adverse reactions

Table 5 presents the adverse reactions identified in the paediatric population with NF1 who have inoperable PN and in adult patients (see footnote to Table 5). The frequency is determined from the paediatric pool (N=74); comprising 50 patients from the pivotal SPRINT Phase II Stratum 1 dataset and 24 patients from the supportive SPRINT Phase I dataset. Adverse drug reactions (ADRs) are organised by MedDRA system organ class (SOC). Within each SOC, preferred terms are arranged by decreasing frequency and then by decreasing seriousness. Frequencies of occurrence of adverse reactions are defined as: very common (u22651/10); common (u22651/100 to <1/10); uncommon (u22651/1,000 to <1/100); rare (u22651/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from available data), including isolated reports.

Table 5. Adverse drug reactions reported in the paediatric pool (pivotal SPRINT Phase II Stratum 1 [N=50] and supportive SPRINT Phase I [N=24]) and in other identified clinical trials in adult patients (N= 347)

MedDRA SOC MedDRA Term Overall Frequency (All CTCAE grades) NF1 paediatric pool u2021 (N= 74) Frequency of CTCAE grade 3 and Above u2020 NF1 paediatric pool u2021 (N= 74)

Eye disorders Vision blurred^ Very common (15 %) - Retinal pigment epithelial detachment (RPED)/Central serous retinopathy (CSR)* u2020u2020 Uncommon (0,6 %) - Retinal vein occlusion (RVO)* u2020u2020 Uncommon (0,3 %) - Respiratory, thoracic & mediastinal disorders Dyspnoea* Common (8 %) - Gastrointestinal disorders Vomiting^ Very common (86 %) Common (9 %) Diarrhoea^ Very common (81 %) Very common (15 %) Nausea^ Very common Common (3 %)(77 %) Stomatitis^ Very common (55 %) Common (1 %) Dry mouth Common (5 %) - Skin and subcutaneous tissue disorders Dry skin Very common (65 %) Common (1 %) Dermatitis acneiform^ Very common (61 %) Common (4 %) Paronychia^ Very common (57 %) Very common (14 %) Rashes (non-acneiform)^* Very common (53 %) Common (3 %) Hair changes^* Very common (39 %) - General disorders Pyrexia Very common (61 %) Common (8 %) Asthenic events* Very common (59 %) - Peripheral oedema* Very common (31 %) - Facial oedema* Common (8 %) - Investigations Blood CPK increased^ Very common (77 %) Common (9 %) Haemoglobin decreased* Very common (54 %) Common (3 %) Hypoalbuminaemia Very common (51 %) - AST increased Very common (51 %) Common (1 %) ALT increased Very common (39 %) Common (3 %) Blood creatinine Very common Common (1 %)increased (32 %) Ejection fraction decreased^ Very common (28 %) Common (1 %) Increased blood pressure* Very common (18 %) - Per National Cancer Institute CTCAE version 4,03 CPK = creatine phosphokinase; AST = aspartate aminotransferase; ALT = alanine aminotransferase

^See Description of selected adverse reactions

u2020All reactions were CTCAE grade 3, except for one CTCAE grade 4 event of blood CPK increased and one CTCAE grade 4 event of blood creatinine increased. There were no deaths.

u2020u2020 Identified ADRs from other clinical trial experience in adult patients (N = 347), with multiple tumour types, receiving treatment with KOSELUGO (75 mg twice daily). These ADRs have not been reported in paediatric population with NF1 who have inoperable PN.

u2021Paediatric pool (N=74) percentage rounded to the nearest decimal.

*ADRs based on grouping of individual preferred terms (PT): Asthenic events: asthenia, fatigue CSR/RPED: Detachment of macular retinal pigment epithelium, chorioretinopathy Dyspnoea: dyspnoea exertional, dyspnoea, dyspnoea at rest Facial oedema: face oedema, periorbital oedema Haemoglobin decreased: anaemia, haemoglobin decreased Hair changes: alopecia, hair colour change Increased blood pressure: blood pressure increased, hypertension Peripheral oedema: oedema peripheral, oedema, localised oedema, peripheral swelling Rashes (non-acneiform): rash pruritic, rash maculo-papular, rash papular, rash, rash erythematous, rash macular

Description of selected adverse reactions

Left ventricular ejection fraction (LVEF) reduction In SPRINT, Phase II Stratum 1, LVEF reduction (PT: ejection fraction decreased) was reported in 13 (26 %) patients; all cases were grade 2, asymptomatic and did not lead to discontinuation; one (2 %) case led to dose interruption then reduction. Of the 13 patients, 11 patients recovered and for 2 patients the outcome was not reported. The median time to first occurrence of LVEF reduction was 232 days (median duration 252 days). The majority of LVEF reduction adverse reactions were reported as reductions from baseline (u226510 % reduction) but were considered to remain in the normal range. Patients with LVEF lower than the institutional LLN at baseline were not included in the pivotal study. In addition, a small number of serious cases of LVEF reduction associated with KOSELUGO have been reported in paediatric patients who participated in an expanded access program. For clinical management of LVEF reduction (see sections 4.2 and 4.4).

Ocular toxicity

In SPRINT, Phase II Stratum 1, grade1 and 2 adverse reactions of blurred vision were reported in 7 (14 %) patients. Two patients required dose interruption. All adverse reactions were managed without dose reduction. For clinical management of new visual disturbances (see sections 4.2 and 4.4).

In addition, a single event of RPED was reported in a paediatric patient receiving KOSELUGO monotherapy (25 mg/m2 twice daily) for pilocytic astrocytoma involving the optic pathway in an externally sponsored paediatric study (see sections 4.2 and 4.4).

Paronychia

In SPRINT, Phase II Stratum 1, paronychia was reported in 28 (56 %) patients, the median time to first onset of maximum grade paronychia adverse reaction was 423 days and the median duration of adverse reactions was 51 days. The majority of these adverse reactions were grade 1 or 2 and were treated with supportive or symptomatic therapy and/or dose modification. Grade u22653 events occurred in 4 (8 %) patients. Ten patients (3 with a maximum grade 3 adverse reaction and 7 with a maximum grade 2 adverse reaction) had a KOSELUGO dose interruption for adverse reactions of paronychia, of whom 5 had dose interruption followed by dose reduction (2 patients required a second dose reduction). In one patient (2 %) the event led to discontinuation.

Blood creatine phosphokinase (CPK) increase

Adverse reactions of blood CPK elevation occurred in 39 (78 %) of patients in SPRINT Phase II Stratum 1. The median time to first onset of the maximum grade CPK increase was 112 days and the median duration of adverse reactions was 153 days. The majority of adverse reactions were grade 1 or 2 and resolved with no change in KOSELUGO dose. Grade u22653 adverse reactions occurred in 3 (6 %) patients. A grade 4 adverse reaction led to treatment interruption followed by dose reduction.

Gastrointestinal toxicities

In SPRINT, Phase II Stratum 1, vomiting (43 patients, 86 %, median duration 3 days), diarrhoea (37 patients, 74 %, median duration 6 days), nausea (36 patients, 72 %, median duration 15 days), and stomatitis (26 patients, 52 %, median duration 27 days) were the most commonly reported gastrointestinal (GI) reactions. The majority of these cases were grade 1 or 2 and did not require any dose interruptions or dose reductions. Grade 3 adverse reactions were reported for diarrhoea (8 patients, 16 %), nausea (2 patients, 4 %), and vomiting (4 patients, 8 %). For one patient diarrhoea led to dose reduction and subsequent discontinuation. No dose reduction or discontinuation was required for adverse reactions of nausea, vomiting or stomatitis.

Skin toxicities

In SPRINT, Phase II Stratum 1, dermatitis acneiform was observed in 28 (56 %) patients (median time to onset 43 days; median duration of 202 days for the maximum CTCAE grade event). The majority of these cases were grade1 or 2, observed in post-pubertal patients (>12 years) and did not require any dose interruptions or reductions. Grade 3 adverse reactions were reported in 3 (6 %) patients.

Other (non-acneiform) rashes were observed in 27 (54 %) patients in the pivotal study and were predominantly grade 1 or 2.

Hair changes

In SPRINT, Phase II Stratum 1, 16 (32 %) of patients experienced hair changes (reported as hair lightening [PT: hair colour changes] in 12 patients (24 %) and hair thinning [PT: alopecia] in 12 patients (24 %)); in 8 patients (16 %) both alopecia and hair colour changes were reported during treatment. All cases were grade 1 and did not require dose interruption or dose reduction.

There is no specific treatment for overdose. If overdose occurs, patients should be closely monitored for signs and symptoms of adverse reactions and treated supportively with appropriate monitoring as necessary. Dialysis is ineffective in the treatment of overdose.